Wexler RR - Search Results

1

Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.

Ladziata VU, Glunz PW, Zou Y, Zhang X, Jiang W, Jacutin-Porte S, Cheney DL, Wei A, Luettgen JM, Harper TM, Wong PC, Seiffert D, Wexler RR, Priestley ES. Ladziata VU, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 2016 Oct 15;26(20):5051-5057. doi: 10.1016/j.bmcl.2016.08.088. Epub 2016 Aug 28. Bioorg Med Chem Lett. 2016. PMID: 27612545

2

The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist.

Duncia JV, Carini DJ, Chiu AT, Johnson AL, Price WA, Wong PC, Wexler RR, Timmermans PB. Duncia JV, et al. Among authors: wexler rr. Med Res Rev. 1992 Mar;12(2):149-91. doi: 10.1002/med.2610120203. Med Res Rev. 1992. PMID: 1619965 Review. No abstract available.

3

The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists.

Timmermans PB, Carini DJ, Chiu AT, Duncia JV, Price WA Jr, Wells GJ, Wong PC, Johnson AL, Wexler RR. Timmermans PB, et al. Among authors: wexler rr. Am J Hypertens. 1991 Apr;4(4 Pt 2):275S-281S. doi: 10.1093/ajh/4.4.275s. Am J Hypertens. 1991. PMID: 1854452 Review.

4

Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3-amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors.

Quan ML, Chiu AT, Ellis CD, Wong PC, Wexler RR, Timmermans PB. Quan ML, et al. Among authors: wexler rr. J Med Chem. 1995 Jul 21;38(15):2938-45. doi: 10.1021/jm00015a016. J Med Chem. 1995. PMID: 7636854

5

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies.

Galemmo RA Jr, Maduskuie TP, Dominguez C, Rossi KA, Knabb RM, Wexler RR, Stouten PF. Galemmo RA Jr, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2705-10. doi: 10.1016/s0960-894x(98)00471-5. Bioorg Med Chem Lett. 1998. PMID: 9873607

6

Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa.

Fevig JM, Cacciola J, Alexander RS, Knabb RM, Lam GN, Wong PC, Wexler RR. Fevig JM, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1998 Nov 17;8(22):3143-8. doi: 10.1016/s0960-894x(98)00574-5. Bioorg Med Chem Lett. 1998. PMID: 9873692

7

Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors.

Dominguez C, Duffy DE, Han Q, Alexander RS, Galemmo RA Jr, Park JM, Wong PC, Amparo EC, Knabb RM, Luettgen J, Wexler RR. Dominguez C, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1999 Apr 5;9(7):925-30. doi: 10.1016/s0960-894x(99)00113-4. Bioorg Med Chem Lett. 1999. PMID: 10230612

8

Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa.

Fevig JM, Buriak J Jr, Stouten PF, Knabb RM, Lam GN, Wong PC, Wexler RR. Fevig JM, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1195-200. doi: 10.1016/s0960-894x(99)00164-x. Bioorg Med Chem Lett. 1999. PMID: 10328312

9

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.

Quan ML, Liauw AY, Ellis CD, Pruitt JR, Carini DJ, Bostrom LL, Huang PP, Harrison K, Knabb RM, Thoolen MJ, Wong PC, Wexler RR. Quan ML, et al. Among authors: wexler rr. J Med Chem. 1999 Jul 29;42(15):2752-9. doi: 10.1021/jm980405i. J Med Chem. 1999. PMID: 10425086

10

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.

Quan ML, Ellis CD, Liauw AY, Alexander RS, Knabb RM, Lam G, Wright MR, Wong PC, Wexler RR. Quan ML, et al. Among authors: wexler rr. J Med Chem. 1999 Jul 29;42(15):2760-73. doi: 10.1021/jm980406a. J Med Chem. 1999. PMID: 10425087

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters